【摘要】 目的探讨新辅助化疗在晚期(Ⅲ~Ⅳ期)子宫内膜癌患者中的应用价值。方法选取2007年1月1日~2016年12月31日我院住院治疗的晚期子宫内膜癌患者53例的临床资料进行回顾性分析。其治疗方法为先行新辅助化疗,然后行手术治疗,手术方式为子宫全切除+双侧附件切除+大网膜阑尾切除+盆腹腔内转移病灶切除术,以残留灶直径≤1cm者为手术满意。评价晚期子宫内膜癌的治疗效果,并分析影响患者预后的因素。结果 53例患者中,残留灶直径≤1 cm者35例,残留灶直径>1cm者18例,手术满意率为66%(35/53)。患者1年生存率为91.1%(41/45),3年生存率为54.3%(19/35),5年生存率为28.6%(6/21)。单因素分析显示,肿瘤侵及范围、有无腹水、术后残留灶大小、明显影响患者的预后(P<0.05)。结论新辅助化疗在晚期子宫内膜癌患者的治疗中有重要价值。更多还原

【Abstract】 Objective To study the clinical value of neoadjuvant chemotherapy in advanced endometiral cacinoma.Methods A retrospective study was carried out in 53 patients with advanced endometrial carcinoma in our hospital from Jan.1,2007 to Dec.31,2016.The treatment method is neoadjuvant chemotherapy before the surgical treatmentincluded total hysterectomy,both adnexectomy,omentectomy,appendectomy and resection of metastatic lesion located in abdomino-pelvic cavity.The criteria of satisfied operation was considered that the sizes of residual leision was smaller than or equal to 1 cm,which was used to evaluate the effect of operation.The prognostic factors were also analyzed.Results Among the 53 cases,The rate of ideal cytoreductive surgery was 66%(35/53),included35 cases of residual leisions size smaller than or equal to 1 cm,while18 cases of residual leisions size larger than 1 cm.The survival rate of 1-year,3-year and 5-year were 91.1%(41/45),54.3%(19/35)and 28.6%(6/21),respectively.The results by single factor analysis shown that the survival rate were intimately correlated withextent of disease,ascites,size of residual leisions.Conclusions Neoadjuvant chemotherapy has important value in advanced endometiral cacinoma.更多还原